Design and development of photoswitchable DFG-Out RET kinase inhibitors

Yongjin Xu1, Chunxia Gao1, Måns Andreasson1

  • 1Department of Chemistry and Molecular Biology, University of Gothenburg, SE, 41296, Gothenburg, Sweden.

Insights

Researchers developed light-controllable kinase inhibitors targeting REarranged during Transfection (RET) to study cancer. A stable 7-azaindole inhibitor showed significant differences in activity between isomers in biochemical and cell-based assays.

Area of Science:

  • Medicinal Chemistry
  • Chemical Biology
  • Oncology

Background:

  • REarranged during Transfection (RET) is a receptor tyrosine kinase crucial for tissue development and implicated in various human cancers.
  • RET activation, through mutations or rearrangements, drives tumor growth and metastasis, making it a key therapeutic target.
  • Small-molecule kinase inhibitors offer a therapeutic strategy, but precise control over their activity remains a challenge.

Purpose of the Study:

  • To develop photoswitchable DFG-out RET kinase inhibitors for non-invasive, light-based control of RET signaling.
  • To investigate the structure-activity relationships of azobenzene-based inhibitors for enhanced light-induced modulation.
  • To create inhibitors with significant differences in biological activity between E and Z isomers for precise spatiotemporal control.

Main Methods:

  • Design and synthesis of heterocycle-derived azobenzene compounds as photoswitchable RET inhibitors.
  • Utilizing quinoline and stilbene scaffolds to guide the development of potent and selective inhibitors.
  • Employing biochemical and cell-based assays to evaluate inhibitor efficacy, isomer-specific activity, and stability.

Main Results:

  • A quinoline-based inhibitor demonstrated over a 15-fold difference in bioactivity between isomers in biochemical assays, but showed reduced selectivity in cellular assays due to stability issues.
  • Stilbene derivatives confirmed the potential for high Z/E activity ratios (>100) in biochemical assays.
  • A 7-azaindole based inhibitor achieved >10-fold bioactivity difference between isomers in both biochemical and cell-based assays, exhibiting excellent stability.

Conclusions:

  • Photoswitchable DFG-out RET kinase inhibitors can be effectively designed for light-controlled modulation of RET signaling.
  • The 7-azaindole scaffold represents a promising platform for developing stable and highly selective photoswitchable kinase inhibitors.
  • This approach holds potential for precise spatiotemporal control of RET signaling in cancer research and therapy.